FDA warns GLP-1 drugs like Ozempic carry rare vision-loss risk

The Food and Drug Administration added a rare vision-loss warning Monday to the labels of Ozempic, Wegovy and every other drug in the GLP-1 class.

The warning covers a dozen injectable and pill-based medications, the blockbuster drugs used to treat obesity, diabetes and several other conditions, the Associated Press reported. The class includes widely prescribed brands such as Zepbound and Mounjaro.

The condition at the center of the warning can cause sudden vision loss and, in severe cases, blindness, STAT News reported. It has shown up in patients taking every GLP-1 drug the FDA reviewed. For a class of medications that has exploded in popularity for weight loss, the label change is the first formal acknowledgment from regulators that the drugs may carry a risk to the eyes.

The condition is called non-arteritic anterior ischemic optic neuropathy, or NAION. Doctors sometimes refer to it as an “eye stroke,” according to STAT. It results from decreased blood flow to the optic nerve, though the FDA said the underlying cause is not understood. There are no proven treatments for it.

The onset is sudden. STAT reported that NAION typically causes sudden vision loss, and the AP said symptoms include blurred vision, blind spots, distorted colors and other visual disturbances. The FDA said patients who experience those problems should contact a health care professional immediately.

FDA scientists opened the review after a 2024 medical paper tied NAION to certain patients taking semaglutide, the active ingredient in Ozempic and Wegovy, the AP reported. STAT had covered that study in July 2024, when researchers linked Ozempic to a higher risk of the eye condition. The investigation expanded from semaglutide to the entire class.

The agency analyzed more than 125 clinical trials. NAION occurred in roughly six of every 100,000 patients who took a GLP-1 drug for at least one year, the FDA said. The rate among patients taking a placebo or other glucose-lowering medications was less than four per 100,000.

The gap is narrow in absolute terms. But the GLP-1 drugs are blockbuster sellers, in the AP’s characterization, and the FDA said it also found reports of the condition in its electronic system for tracking drug injuries and side effects. NBC News reported the warning Monday and described the condition as one linked to sudden blindness.

Novo Nordisk sells Ozempic, approved for diabetes, and Wegovy, approved for weight loss. Both are built on semaglutide. Eli Lilly sells Mounjaro, approved for diabetes, and Zepbound, approved for weight loss. Both are built on tirzepatide. STAT identified the two companies as the makers behind the leading GLP-1 brands.

The drugs have exploded in popularity for their potent weight loss effects, STAT reported. As with any drugs given to large populations, side effects can appear in real-world use that did not surface in clinical trials, the outlet noted. The vision-loss warning arrives as the class continues to grow.

The warning applies to every GLP-1 drug regardless of manufacturer or active ingredient, the AP reported, because the condition has been reported across the class. The FDA is requiring the pharmaceutical companies to inform patients and doctors of the risk, STAT reported. The agency posted a drug safety communication spelling out the label changes.

What I think

The numbers are small. Six cases per 100,000 is a rare event, and the comparison group was not far behind at fewer than four. A person reading the headline and nothing else could conclude that the FDA has found something alarming about the drugs in their medicine cabinet.

That reading is wrong. The FDA did not pull the drugs from the market. It did not restrict who can take them.

It added a warning to the label about a condition that most patients will never encounter, and it told doctors and patients to watch for symptoms and report them. That is what regulators are supposed to do when a signal shows up in the data.

The warning matters because of scale. When a blockbuster drug is taken by a large population, a rare event still reaches a lot of people. NAION has no proven treatment and can cause permanent vision loss. A patient who knows the symptoms can seek care quickly. A patient who does not know may lose sight and never connect it to the injection.

The case for the warning is not that NAION is common. It is that the condition is irreversible, the drugs are everywhere, and the symptoms are specific enough that a warned patient can act on them. A label change costs the manufacturers little and costs patients nothing. The same cannot be said for losing sight without warning.

The debate over GLP-1 drugs has swung between enthusiasm and caution. The drugs produce potent weight loss, as STAT noted, and they also turn up new risks as prescribing widens. The vision warning fits that pattern. It does not change the case for the drugs, but it adds a term to the calculation.

The harder question is whether the benefit still outweighs the risk for any individual. That is a conversation between a patient and a doctor, and it depends on what the patient is treating.

Obesity and diabetes carry their own risks to vision, including diabetic retinopathy, which is far more common than NAION. Stopping a GLP-1 drug is not obviously the safer choice for someone whose diabetes is out of control. But the decision now has one more piece of information in it, and the FDA was right to put it on the label.